Lipitor's Patent Expiration Timeline
Lipitor (atorvastatin), made by Pfizer, lost U.S. patent protection on November 30, 2011, after generating peak annual sales over $12 billion. Generic versions from Teva, Ranbaxy, and others launched immediately, causing branded Lipitor sales to drop 85% within a year.[1][2]
Shift from Direct-to-Consumer Promotion
Before expiration, Pfizer spent heavily on U.S. TV ads and celebrity endorsements (e.g., Dr. Robert Jarvik in 2005-2008 campaigns), positioning Lipitor as a must-have for cholesterol control. Post-patent, direct-to-consumer (DTC) TV advertising stopped almost entirely by 2012, as generics undercut the price and captured 90% market share within months. Promotion pivoted to physicians via detailing and samples, but volume fell sharply.[1][3]
Focus on Authorized Generics and Copay Cards
Pfizer countered generics by launching an authorized generic version in late 2011, matching Teva's price to retain some revenue. They ramped up patient assistance programs and copay savings cards, reducing out-of-pocket costs to $4 per month for cash-paying patients. This kept some loyal users on the branded product, stabilizing sales at around $2 billion annually through 2014.[2][4]
Global Marketing Adjustments
Outside the U.S., where patents expired later (e.g., 2012-2013 in Europe), Pfizer extended DTC efforts briefly but shifted to combo products like Caduet (Lipitor + Norvasc) to differentiate. Emerging markets saw aggressive pricing and partnerships to fight local generics.[3]
Long-Term Strategy: Repositioning and New Formulations
By 2013, marketing emphasized Lipitor's role in combos and higher-risk patients (e.g., post-heart attack). Pfizer introduced extended-release versions and pushed for over-the-counter (OTC) approval (denied in 2013). Sales stabilized via volume in generics and global expansion, but branded promotion never recovered pre-patent levels.[1][4]
Impact on Competitors and Market Share
Generics flooded in, with Watson (now Teva) grabbing 40% share quickly. Pfizer's response delayed full erosion but couldn't halt it—branded Lipitor now holds under 5% U.S. prescriptions. This playbook influenced later patent cliffs for drugs like Nexium.[2]
[1]: FDA Orange Book - Lipitor Patent History
[2]: DrugPatentWatch.com - Lipitor Patent Expiration
[3]: [IMS Health (now IQVIA) Reports on Statin Market, 2012]
[4]: [Pfizer Annual Reports, 2011-2014]